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ABSTRACT
Background: Histamine synthesized by histidine decarboxylase (HDC) from L-histidine is a major chemical
mediator in the development of nasal allergy which is characterized by nasal hypersensitivity. However the
regulatory mechanism of histamine synthesis by HDC remains to be elucidated. The objectives of the present
study were to examine the changes of histamine content, HDC activity and HDC mRNA expression in the nasal
mucosa of allergy model rats sensitized by the exposure to toluene diisocyanate (TDI) and to investigate the ef-
fect of dexamethasone on the above mentioned allergic parameters.
Methods: Rats were sensitized and provocated by TDI and the nasal allergy-like behaviors were scored dur-
ing a 10 minute period after provocation. Histamine content and HDC activity in the nasal mucosa were deter-
mined using fluorometric high performance liquid chromatography. The expression of HDC mRNA in nasal mu-
cosa was determined using real-time quantitative reverse transcriptase-polymerase chain reaction (RT-PCR).
Results: In TDI-sensitized rats, nasal allergy-like behaviors such as sneezing and watery rhinorrhea were in-
duced. Histamine content, HDC activity and HDC mRNA expression in nasal mucosa were also significantly in-
creased after TDI provocation. Pretreatment with dexamethasone significantly suppressed nasal allergy-like
behaviors, up-regulation of histamine content, HDC activity and HDC mRNA induced by TDI in TDI-sensitized
rats.
Conclusions: These findings indicate that increased synthesis of histamine through up-regulation of HDC
gene expression and HDC activity in nasal mucosa plays an important role in the development of nasal hyper-
sensitivity. Repression of HDC gene expression and HDC activity by dexamethasone may underlie its thera-
peutic effect in the treatment of allergy.
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INTRODUCTION
Histamine the major chemical mediator in the devel-
opment of nasal allergy is produced by the decarbox-
ylation of L-histidine via the pyridoxal-requiring en-
zyme histidine decarboxylase (HDC).1 In eukaryotes,
HDC is the primary enzyme responsible for synthe-
sizing histamine and is consequently a crucial regula-
tory step for histamine biosynthesis.2
The HDC molecule is a dimer consisting of two
identical 53 ― 55 kDa subunits 3,4 while the size of
cDNA deduced HDC is around 74 kDa.5,6 The endo-
genous 74 kDa form of HDC is translated in the cy-
tosol and then translocated to the endoplasmic reticu-
lum, where it is post-translationally processed to the
53 kDa form.7,8 The synthesis of histamine by HDC is
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Fig. 1 Protocol for TDI sensitization and provocation. Rats 
were sensitized with 10 μl of 10% TDI in ethyl acetate for 2 
weeks. After 1 week gap provocation was done with 10 μl of 
10% TDI in ethyl acetate. Control rats were sensitized and 
stimulated with ethyl acetate alone by the same procedure.
10%TDI
sensitization
10%TDI
provocation
10%TDI
sensitization
5 days 5 days2 days 1 weekan important regulatory step in histamine signaling
but the regulatory mechanism remains to be eluci-
dated.
Steroidal anti-inflammatory drugs are known to be
the most potent drugs for treatment of the inflamma-
tory and allergic diseases. Various hypotheses on the
mechanisms of anti-inflammatory effects of steroidal
anti-inflammatory drugs have been presented. Recent
studies suggested that one of the most important
mechanisms may be the inhibition of cytokine pro-
duction such as IL1,9,10 TNF11 and platelet-activating
factor . 12 Hirasawa et al. reported that in air pouch
type allergic inflammation model in rats, histamine in
the anaphylaxis phase is released from subcutaneous
mast cells via an IgE-mediated mechanism13 and his-
tamine in the post-anaphylaxis phase is produced
from an increase in the HDC activity . They also
showed that dexamethasone inhibits histamine pro-
duction in allergic inflammation in rats, but the mo-
lecular mechanism remains to be elucidated.
In the present study we hypothesize that in the
post-anaphylaxis phase histamine is produced
through up-regulation of HDC gene expression and
thereby HDC activity . Dexamethasone suppresses
this up-regulation.
In our previous study we developed a nasal hyper-
sensitivity animal model in guinea pigs sensitized by
exposure to toluene diisocyanate (TDI) , which ex-
presses respiratory disorders such as asthma and na-
sal allergy in industrial workers . Those studies
showed that repeated exposure to TDI triggered a
neurogenic inflammatory reation in the nasal mucosa
correlative to the release of histamine, resulting in
the development of nasal allergy-like behaviors in
guinea pigs.14,15
In the present study we used TDI-sensitized rats as
an animal model of nasal hypersensitivity and investi-
gated the changes in nasal symptoms, histamine lev-
els, HDC activity and HDC gene expression in the na-
sal mucosa . The effect of dexamethasone on the
above mentioned parameters in the nasal mucosa in-
duced by TDI were also examined.
METHODS
TDI SENSITIZATION AND PROVOCATION
Six-week-old male Brown Norway rats (Nihon Char-
les River, Kanagawa, Japan) were used for the pre-
sent study. The rats were kept in a room maintained
at a constant temperature (25 ± 2℃) and humidity (55
± 10%) with a 12 hour lightdark cycle. Sensitization
to TDI was performed by the method described by
Tanaka et al.16 with slight modifications. Briefly, 10 μl
of a 10% solution of TDI (Wako Chemical Co., Tokyo,
Japan) in ethyl acetate (Wako Chemical Co . ) was
painted bilaterally on the nasal vestibule once a day
for five consecutive days (sensitization). This sensiti-
zation procedure was then repeated after a 2-day in-
terval. Seven days after the second sensitization, 10 μl
of 10% TDI solution was again applied to the nasal
vestibule to provoke nasal allergy-like behaviors in
the sensitized rats (provocation)(Fig. 1). Control rats
were treated with ethyl acetate , the vehicle by the
same procedure . Nasal allergy-like behaviors were
measured by the number of sneezes and the extent of
watery rhinorrhea on a scale ranging from zero to
three (Table 1) during a 10-minute period just after
provocation by the method of Abe et al.14
All animal experiments were approved by the Ethi-
cal Committee for Animal Studies of School of Medi-
cine, the University of Tokushima.
PRETREATMENT WITH DEXAMETHASONE
Dexamethasone (Wako Chemical Co.) was adminis-
tered intraperitoneally 24 hours before TDI provoca-
tion at the dose of 1 mgkg. In the saline-pretreated
group, saline was administered instead of the drug.
COLLECTION OF NASAL MUCOSA AND ISOLA-
TION OF TOTAL RNA
At different indicated periods of time after provoca-
tion, rats were sacrificed and nasal mucosa was re-
moved from the nasal septum. Samples were frozen
in RNA later (Takara Biochemicals, Tokyo, Japan)
and stored in a tube at −84℃ until assayed . Total
RNA was isolated using TRIzol reagent (Invitrogen
Corp., Carlsbad, CA, USA) according to the manufac-
turer’s instructions. In short, nasal mucosa was ho-
mogenized using Polytron (Model PT-K; Kinematica
AG, LittauLuzern, Switzerland) in 10 volumes of ice-
cold TRIzol Reagent until complete disruption. The
homogenates were mixed with chloroform and centri-
fuged at 12,000 × g for 15 minutes at 4℃. The aque-
ous phase containing RNA was transferred to a new
tube and the RNA was precipitated by the addition of
isopropanol. Samples were incubated at room tem-
perature for 5 minutes and centrifuged at 12,000 × g
for 15 minutes at 4℃. The RNA pellet was washed
with 70% ice-cold ethanol, air-dried and dissolved in
20 μl of diethylpyrocarbonate-treated water. The pu-
rity and yield of total RNA were determined spectro-
photometrically at 260 and 280 nm. The ratio of ab-
sorption (260 : 280) of all preparations was >1.8.
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Fig. 2A Time course study of histamine content in the na-
sal mucosa after TDI provocation. ■: TDI-sensitized group; 
◆ : control group. Points represent means ± SE. ＊ P ＜ 
0.01 compared with vehicle-treated control (n＝4).
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Fig. 2B Efect of dexamethasone (1 mg/kg) on up-regula-
tion of histamine content after TDI provocation. ■: TDI-
sensitized group; ◆: control group; ▲: TDI＋ Dexamethasone.
Points represent means ± SE. ＊P ＜ 0.01 compared with 
TDI only group (n＝4); ★ P ＜ 0.01 compared with vehicle-
treated control group (n＝4).
0
1
2
3
4
5
6
7
0 3 6 9 12 15
Time (hr)
H
is
ta
m
in
e 
(p
m
ol
/m
g 
pr
ot
ei
n)
＊
＊
Table 1 Criteria for grading the severity of TDI-induced nasal alergy-like behavior in rats.
3210Score
12＜5―111―4(－)Number of sneezes
drops of discharge
from the nose
between 1 and 3at the nostril(－)Watery rhinorhea
Table 2 Efect of Dexamethasone on TDI-induced nasal symptoms
TDI treated
pretreated with Dexamethasonepretreated with salineControl
3.3 ± 0.4＊5.2 ± 0.30
＊P＜0.01 compared with saline pretreated group.
REAL-TIME QUANTITATIVE REVERSE
TRANSCRIPTASE-POLYMERASE CHAIN REAC-
TION (REAL-TIME RT-PCR)
RNA samples were reverse-transcribed to cDNA in a
40 μl reaction volume in the presence of first-strand
buffer (375 mM KCl, 250 mM Tris-HCl, pH 8.3, at
room temperature), 15 mM MgCl2, 0.8 mM concen-
trations of each deoxyribonucleoside triphosphate
(dNTP), 40 μM of oligo (dT) primers, 0.004 units of
RNase inhibitor, 8 units of reverse transcriptase and
were incubated at 37℃ for 60 minutes. Then 2 μl of
2N NaOH was added before they were incubated
again at 65℃ for 30 minutes. Subsequently, 12.8 μl of
1 M Tris-HCl, pH 8.0, was added before samples were
heated at 95℃ for 10 minutes and chilled to 4℃ for 5
minutes. TaqMan primers and probe were designed
using Primer Express software (Perkin Elmer Ap-
plied Biosystems, Foster City , CA, USA). The se-
quences of the primers were as follows: sense primer
5´ -GCA GCA AGG AAG AAC AAA ATC C-3 ´ ; an-
tisense primer 5 ´ -CAA CAA GAC GAG CGT TCA
GAG A-3´. The sequence of the probe was as follows:
FAM-AAA GCG CAT GAG CCC AAT GCT GAT-
TAMRA. To account for differences in starting mate-
rial , rodent glyceraldehyde-3-phosphate dehydroge-
nase (GAPDH) primers and probe from Applied Bio-
systems were used as recommended by the manufac-
turer. The transcripts were utilized for a 40-cycle 3-
step PCR using the GeneAmp 5700 Sequence Detec-
tion System (Perkin Elmer Applied Biosystems) in 20
mM Tris, pH 8.4, 50 mM KCl, 3 mM MgCl2, 200 μM
dNTPs, 900 nM concentrations of each primer and
0.25 units of Platinum Taq. Amplicon size and reac-
tion specificity were confirmed by agarose gel elec-
trophoresis . The identity of the PCR products was
verified by sequencing using a DNA sequencer
(4200 L-1; Aloka, Tokyo, Japan).
The number of target copies in each sample was in-
terpolated from its detection threshold (CT) value us-
ing a purified PCR product standard curve included
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Fig. 3A Time course study of HDC activity in the nasal mu-
cosa after TDI Provocation. ■ : TDI-sensitized group; ◆ : 
control group. Points represent means ± SE.＊ P ＜ 0.01 
compared with vehicle-treated control (n＝4).
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Fig. 3B Efect of dexamethasone (1 mg/kg) on up-regula-
tion of HDC activity after TDI provocation. (● ): TDI-sensi-
tized group. (○ ): TDI＋ Dexamethasone group. (▲ ): 
control group. Points represent means ± SE. ＊ P ＜ 0.01 
compared with TDI only group (n＝ 4); ★ P ＜ 0.01 com-
pared with vehicle treated control group (n＝4) .
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on each plate. Each PCR run included the four points
of the standard curve ( four fold serially diluted
cDNA), a no template control, the calibrator cDNA
and the unknown cDNAs. The measurements were
calibrated using the calibrator included on each PCR
plate. For the quantification of gene expression, we
used GAPDH mRNA as the endogenous control. To
determine whether the amplification products came
exclusively from the RNA , a reverse-transcriptase
negative reaction was run in which the enzyme was
replaced by RNase-free water for each sample.
HDC ACTIVITY AND HISTAMINE CONTENT
Nasal mucosa was homogenized with 10 volumes of
ice-cold HDC buffer solution, which consisted of 0.1
M potassium phosphate buffer (pH 6―8) , 0.2 mM
dithiothreitol , 0.01 mM pyridoxal 5´ -phosphate , 1%
polyethylene glycol (average molecular weight 300)
and 100 μgml phenylmethylsulfonyl fluoride.17 The
homogenates were centrifuged at 10,000 g for 15 min-
utes at 4℃ and the supernatant (supernatant A) was
collected . Half of the supernatant A was dialyzed
three times against adequate volume of HDC buffer
solution for 6 hours at 4℃ (supernatant B).
Histamine content in supernatant A was deter-
mined using a high-performance liquid chromatogra-
phy (HPLC) with a cation exchanger (Tosoh, Tokyo,
Japan) and an automated o-phthalaldehyde fluoromet-
ric detection system (Hitachi, Tokyo, Japan) in accor-
dance with the method of Yamatodani et al.18
HDC activity was determined by incubating super-
natant B for 4 hours at 37℃ with 0.25 mM L-histidine.
HDC activities were calculated based on the forma-
tion of histamine after the subtraction of blank value.
The protein concentrations of these preparations
were determined by the method of Lowry et al.19 in
triplicate with bovine serum albumin as a standard.
STATISTICAL ANALYSIS
The results are presented as mean±standard error
(SE). All P values were determined by using one-way
ANOVA and Fisher’s paired least-significant differ-
ence test. P values less than 0.05 were considered sig-
nificant.
RESULTS
NASAL ALLERGY-LIKE BEHAVIORS
Intranasal application of TDI induced nasal allergy-
like behaviors such as sneezing and watery rhinor-
rhea in sensitized rats . The total score of nasal
allergy-like behaviors was 5.2. Pretreatment with dex-
amethasone (1 mgkg i.p.) significantly reduced na-
sal allergy-like behaviors, of which total score was re-
duced to 3.3 (Table 2). However, control rats sensi-
tized by exposure to vehicle showed no nasal allergy-
like behaviors after provocation.
HISTAMINE CONTENT
As histamine is the prime chemical mediator in the
development of nasal allergy, we measured the hista-
mine content in nasal mucosa at different time after
TDI provocation and observed the effect of dex-
amethasone on it. The histamine content in nasal mu-
cosa was significantly increased after TDI provoca-
tion in sensitized rats (Fig. 2A). The maximum level
was achieved after 9 hours of provocation . Dex-
amethasone (1 mgkg, i.p.) showed significant inhibi-
tory action on it (Fig. 2B).
HDC ACTIVITY
To confirm whether increased synthesis of histamine
is mediated through HDC activity , a time course
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Fig. 4A Time course study of HDC mRNA expression in 
the nasal mucosa after TDI provocation. Filed circles: TDI-
sensitized group; open circles: control group. Points repre-
sent means ± SE. ＊P ＜ 0.01 compared with the vehicle-
treated control (n＝4).
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Fig. 4B Efect of dexamethasone (1 mg/kg) on up- regula-
tion of HDC mRNA after 4 hr and 12 hr of TDI provocation. 
■ : TDI-sensitized group; ◆ : control group; ▲ : TDI ＋ 
Dexamethasone. Points represent means ± SE. ＊ P ＜ 
0.01 compared with TDI only group (n＝ 4); ★ P ＜ 0.01 
compared with vehicle-treated control group (n＝4).
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study was also done to investigate the HDC activity at
different time intervals after TDI provocation. HDC
activity in the nasal mucosa was significantly in-
creased after provocation in TDI sensitized rats (Fig.
3A). The HDC activity reached a maximum over the
initial level after 9 hours of provocation. Pretreatment
with dexamethasone (1 mgkg , i . p . ) almost com-
pletely suppressed HDC activity both 9 hours and 15
hours after provocation (Fig. 3B).
HDC mRNA EXPRESSION
In an attempt to confirm the molecular mechanism of
HDC activity up- regulation, the effect of TDI on HDC
gene expression in the nasal mucosa was performed
using real-time PCR. The HDC mRNA expression
was significantly increased after provocation in sensi-
tized rats compared to control (Fig. 4A).
The increase of HDC mRNA in the nasal mucosa
was observed 1 hour after provocation and reached a
maximum ( 6 times over the initial level ) after 4
hours. The level of HDC mRNA returns close to its
baseline within 24 hours . Pretreatment with dex-
amethasone (1 mgkg, i.p.) significantly suppressed
HDC transcription in both 4 hours and 12 hours after
provocation (Fig. 4B).
DISCUSSION
In the present study, intranasal application of TDI in-
duced nasal allergy-like behaviors, such as sneezing
and watery rhinorrhea in TDI-sensitized rats . This
finding corroborates the results of our previous stud-
ies that showed the trigger of such behaviors after
TDI stimulation . We also have reported that TDI-
sensitization enhances the synthesis of substance P
and calcitonin-gene related peptide in the trigeminal
ganglion neurons as well as their axonal transport
and antidromic release towards the peripheral end-
ings.14,15 Moreover, substance P and calcitonin-gene
related peptide has been reported to induce the re-
lease of histamine from mast cells in the nasal mu-
cosa.14 This observation has been confirmed by re-
ports showing that both the histamine content and
number of mast cells in nasal mucosa were higher in
TDI-sensitized guinea pigs as compared to con-
trols.16,20,21
Nasal allergy-like behaviors during 10 minutes just
after provocation was studied to check the effect of
dexamethasone on the anaphylaxis phase which is
due to the release of preformed histamine during the
sensitization process. Dexamethasone improves nasal
allergy-like behaviors by suppressing the release of
inflammatory mediators from mast cells and other
types of cells. It also suppresses proliferation of acti-
vated lymphocytes, mast cell development and matu-
ration and expression of FcεRI . 22-26 Although this
data is not relevant for the present study it does sup-
port the previous studies.
In addition, the expression of HDC mRNA in the
nasal mucosa was significantly increased after TDI
provocation in sensitized rats (Fig. 4A). This finding
is in line with studies in which the HDC mRNA level
was increased in patients with allergic rhinitis and
bronchial asthma . 27,28 HDC activity and histamine
content in the nasal mucosa were also significantly in-
creased after TDI provocation (Figs . 2A, 3A), sug-
gesting that HDC gene expression is an important
step in histamine signaling pathways in allergic re-
sponses.
We also examined the effect of dexamethasone on
the up-regulation of histamine content, HDC activity
and gene expression after intranasal application of
TDI in TDI-sensitized rats. Our results in this study
demonstrate that pretreatment with dexamethasone
significantly suppressed the increase of histamine
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content, HDC activity and HDC mRNA expression in
the nasal mucosa after provocation (Figs . 2B―4B).
Since histamine is the major chemical mediator for al-
lergy , it is suggested that pretreatment with dex-
amethasone improves allergic diseases by its inhibi-
tory effect on histamine synthesis. Histamine synthe-
sis in vivo is regulated through either the translation
or transcription stage or through both. HDC mRNA
was suppressed approximately by half the level
whereas HDC activity was almost completely sup-
pressed by dexamethasone . These results indicate
that dexamethasone exhibit it’s inhibitory effect both
at the transcription and translation level. At present
we have no data to describe precisely the step be-
tween mRNA transcription and matured protein with
enzymatic activity inhibited by dexamethasone. Sup-
pression of HDC mRNA may be due to a decrease in
RNA transcription rate or RNA stability. We have yet
to determine which of these mechanisms might ac-
count for the decrease of HDC mRNA, but we sus-
pect that a reduction in transcription rate may be in-
volved . Concordantly HDC enzymatic activity sup-
pression may be mediated by low rates of translation
or rapid degradation of HDC protein. Due to lack of
sufficient data, we are currently unable to explain the
exact reason behind this . Sequence analysis of rat
HDC gene has identified several putative regulatory
elements , including activator protein (AP) -1, AP-2,
Oct-1, Sp-1, CCAAT boxes, hypoxia inducible factor
(HIF) -1 binding sites and five GRE-like consensus
sites.2 It is well established that GR interacts with c-
Jun homodimers or c-Jun-c-Fos heterodimers (AP-1)
before DNA binding and results in inhibition of their
abilities to activate the transcription rate.29
In agreement with our results, several studies in
rat and mouse lung have shown that glucocorticoid
hormones may be involved in the regulation of HDC
enzyme activity.30-32 Cynthia A et al. showed that glu-
cocorticoid hormones down-regulate HDC mRNA
and enzyme activity in lung but failed to show any
down-regulation of histamine content in normal rats.2
It may be due to short time treatment of dexametha-
sone. In order to clarify this phenomenon, in the pre-
sent study we treated rats with dexamethasone for a
long time period ( 24 hours ) and found that dex-
amethasone improves allergic diseases through sup-
pression of histamine synthesis. Maeda et al. showed
that HDC activity in human mast cell line HMC-1 in-
duced by PMA and Inomycin is regulated at the
translation level as this activity was inhibited by cy-
clohexamide but not by actinomycin D.33 In human
basophilic leukemia KU-812-F cells , induction of
HDC activity by PMA is regulated at the translation
level as well.34 Whereas in murine macrophage-like
cell line RAW 264.7, induction of histamine produc-
tion by thapsigargin was due to the increased expres-
sion of HDC protein and dexamethasone inhibited
thapsigargin-induced HDC protein expression and
histamine production via inhibition of MAP kinase ac-
tivation.35
In contrast to our studies , glucocorticoids have
been shown to activate HDC expression in mastocy-
toma and basophilic leukemia cell lines . 36 Experi-
ments with cell lines provide valuable information but
must be interpreted with caution because they do not
precisely duplicate the conditions and the multiple
variables that exist in the whole animal. On the other
hand according to the article, the transcription start-
ing site was tentatively identified, but the possibility
that the transcription starts from multiple sites was
excluded. This may be one of the reasons for the dis-
crepancy in the effects of dexamethasone between in-
vivo and in-vitro studies . Dexamethasone increased
both histamine content and the de novo synthesis of
HDC from cultured mouse mastocytoma p 815 cells
and cultures of rat hepatic cells.31,37 This regulation
was further studied by examining the synergistic ef-
fects of glucocorticoids and the protein kinase C
(PKC) activator 12-O-tetradecannoylphorbol 13 ace-
tate ( TPA ) on HDC synthesis from mouse p 815
cells.38 Previously, it had been shown that activation
of PKC may be involved in the glucocorticoid hor-
mone induced synthesis of HDC in mouse mastocy-
toma cells.38 Taken together, these results suggest
that the effects of glucocorticoid hormones on HDC
activity may be tissue or cell specific.
Several studies have been done previously for in-
vestigating the sources of histamine in vivo. Hista-
mine is produced by mast cells , basophilic cells ,
macrophages, neutrophils and lymphocytes.39-41 Mast
cells and basophilic cells constitutively express HDC
of 74 and 53 kDa molecular masses and store the pro-
duced histamine in their granules.42 Other types of
cells produce histamine in response to various stimu-
lants and release it piecemeal.35 In the present study
we did not check the sources of histamine produced
in TDI-sensitized allergic rats but speculate that all of
the above mentioned cells were the sources of hista-
mine.
Clinically, histamine plays a key role in producing
nasal symptoms and glucocorticoids constitute the
most potent treatment in nasal allergy. In fact, gluco-
corticoids have a strong anti-inflammatory capacity in
reducing cytokine and chemokine release and are
able to decrease the cellular infiltration of antigen
presenting cells, T cells and eosinophils in the nasal
mucosa.43 Current pharmacotherapy for nasal allergy
also includes H1-antihistamines. However, in our pre-
liminary study, d-chlorpheniramine did not suppress
the TDI-induced up-regulation of HDC mRNA. There-
fore, the suppression of up-regulation of HDC mRNA
and HDC activity may be the mechanisms responsi-
ble for the superiority of dexamethasone to H1 anti-
histamines in the treatment of nasal allergy.
In conclusion, we used TDI-sensitized rats as an
animal model of nasal hypersensitivity induced by
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neurogenic inflammation and showed that the up-
regulation of HDC mRNA in nasal mucosa plays an
important role in the development of nasal hypersen-
sitivity . Dexamethasone significantly reduced nasal
allergy-like behaviors, up-regulation of HDC mRNA,
HDC activity and histamine content induced by TDI.
These results suggest that the suppression of the up-
regulation of HDC genes and HDC enzymatic activity
by dexamethasone may underlie its therapeutic effect
in the treatment of allergies.
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